Aigen Investment Management LP Invests $233,000 in Novartis AG (NYSE:NVS)

Aigen Investment Management LP bought a new stake in shares of Novartis AG (NYSE:NVS - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 2,394 shares of the company's stock, valued at approximately $233,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Concurrent Investment Advisors LLC lifted its position in shares of Novartis by 11.8% during the third quarter. Concurrent Investment Advisors LLC now owns 3,734 shares of the company's stock worth $429,000 after purchasing an additional 393 shares during the last quarter. CWA Asset Management Group LLC bought a new position in Novartis during the 3rd quarter worth approximately $2,953,000. Equitable Trust Co. acquired a new position in shares of Novartis in the 3rd quarter worth approximately $229,000. SpiderRock Advisors LLC acquired a new stake in shares of Novartis during the 3rd quarter valued at approximately $1,291,000. Finally, Assetmark Inc. lifted its stake in Novartis by 4.8% during the third quarter. Assetmark Inc. now owns 223,996 shares of the company's stock worth $25,764,000 after purchasing an additional 10,290 shares during the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on NVS shares. Morgan Stanley began coverage on shares of Novartis in a research report on Wednesday, February 12th. They issued an "underweight" rating on the stock. HSBC downgraded Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a research report on Tuesday, February 4th. Barclays restated an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. Finally, StockNews.com upgraded Novartis from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 8th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $123.38.

Remove Ads

Novartis Price Performance

NYSE NVS traded down $3.46 on Tuesday, reaching $112.01. The company's stock had a trading volume of 1,082,078 shares, compared to its average volume of 2,045,338. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04. The firm's 50 day moving average is $104.38 and its two-hundred day moving average is $107.87. The stock has a market cap of $228.95 billion, a PE ratio of 19.05, a PEG ratio of 1.70 and a beta of 0.53.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. As a group, sell-side analysts predict that Novartis AG will post 8.45 EPS for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.